Your browser doesn't support javascript.
loading
Pharmacological treatments for psychotic symptoms in dementia: A systematic review with pairwise and network meta-analysis.
Huang, Yu-Yuan; Teng, Teng; Shen, Xue-Ning; Chen, Shi-Dong; Wang, Rong-Ze; Zhang, Rui-Qi; Dou, Kai-Xi; Zhong, Xiao-Ling; Wang, Jun; Chen, Ke-Liang; Zhao, Qian-Hua; Tan, Lan; Dong, Qiang; Zhou, Xin-Yu; Yu, Jin-Tai.
Afiliação
  • Huang YY; Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China.
  • Teng T; Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Shen XN; Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China.
  • Chen SD; Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China.
  • Wang RZ; Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China.
  • Zhang RQ; Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China.
  • Dou KX; Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Zhong XL; Department of Neurology, Qingdao Central Hospital, Qingdao University, Qingdao, China.
  • Wang J; Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.
  • Chen KL; Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China.
  • Zhao QH; Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China.
  • Tan L; Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
  • Dong Q; Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China.
  • Zhou XY; Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Yu JT; Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: jintai_yu@fudan.edu.cn.
Ageing Res Rev ; 75: 101568, 2022 03.
Article em En | MEDLINE | ID: mdl-35051646
ABSTRACT
Psychotic symptoms of dementia are highly prevalent and lead to poor medical outcomes and substantial dysfunction. To date, which drug to use remains controversial without a summary of all direct or indirect comparisons of pharmacotherapy. Therefore, we conducted a systematic review with pairwise and network meta-analysis to examine efficacy and tolerability outcomes of pharmacological treatments in dementia patients. MEDLINE, Cochrane Library, EMBASE, and PubMed were searched systematically up to August 31, 2020. We included trials of cholinesterase inhibitors (ChEIs), memantine, antipsychotics, antidepressants, and mood stabilizers, with final approval from the U.S. Food and Drug Administration. We ranked the comparative effects of all drugs against placebo with surface under the cumulative ranking (SUCRA) probabilities. This analysis is based on 34 trials, which included 10,415 patients randomly assigned to 15 commonly used drug regimens. Donepezil (standardized mean difference [SMD] -0.30, 95% credible interval [CrI] -0.50 to -0.12; SUCRA, 0.85), memantine (SMD -0.20, 95%CrI -0.34 to -0.07; SUCRA, 0.68) and aripiprazole (SMD -0.17, 95% CrI -0.32 to -0.02; SUCRA, 0.62) showed greater benefit than placebo, and with relatively good tolerability in network meta-analyses. Risperidone was also found to be more efficacious than placebo (SMD -0.16, 95% CrI -0.28 to -0.05; SUCRA, 0.60), but with poor tolerability (odds ratios [OR] 1.50, 95% CrI 1.06-2.26). Donepezil, memantine, haloperidol, aripiprazole and risperidone were more efficacious than quetiapine (SMDs ranged from -0.36 to -0.22). Besides, donepezil, memantine and mirtazapine were more efficacious than sertraline (SMDs ranged from -0.47 to -0.36). Most of the results were rated as "low" to "very low". Several effective treatment choices for psychotic symptoms are available across drug classes. Donepezil, memantine and aripiprazole are probably the appropriate options to consider when a pharmacological treatment is indicated. Given the limitations of the meta-analytic approach and the low methodological quality of the majority of studies, our results should be cautiously interpreted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Risperidona / Demência Tipo de estudo: Clinical_trials / Diagnostic_studies / Systematic_reviews Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Ageing Res Rev Assunto da revista: GERIATRIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Risperidona / Demência Tipo de estudo: Clinical_trials / Diagnostic_studies / Systematic_reviews Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Ageing Res Rev Assunto da revista: GERIATRIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China